By Editorial TeamThe hype around generative AI is deafening, but for investors looking at health tech, it’s mostly noise. When a patient’s life is on the line, you can’t use the same tech that powers chatbots. While large language models (LLMs) are getting all the press, the real work in diagnostic cardiology is still being done with a much more precise and proven technology: structured deep learning. This is a roadmap for early-stage VCs to help you see the difference between real clinical value and a slick marketing deck.
The Inherent Limitations of Generative AI in Diagnostic Precision
Generative AI, including LLMs, works by finding patterns in massive, messy datasets to create new text or images that look like a human made them. That’s a powerful tool for a lot of things, but it’s a huge liability in clinical diagnostics, especially for something like cardiology where a tiny blip on a screen can be the difference between life and death. The biggest problem is that these models “hallucinate”, they just make things up that sound plausible but are factually wrong. Stanford Medicine research on clinical LLM hallucinations has shown over and over how these models confidently present incorrect information in a clinical setting. In cardiology, a false negative from a hallucinating AI could be fatal, while a false positive could send a patient for an unnecessary, invasive procedure. That level of unreliability is a non-starter, which is why the FDA’s strict requirements for Software as a Medical Device (SaMD) demand verifiable accuracy and predictable performance that today’s generative models just can’t guarantee for diagnostic work.
Structured Deep Learning: The Bedrock of Clinical Cardiology AI
Structured deep learning models are the complete opposite, built to find specific, known patterns within clean, well-organized, and labeled data. These models get trained on huge libraries of real patient data, often combining ECG waveforms, MRI images, and even genomic sequences, to learn the complex connections between a signal and a clinically proven diagnosis. This is exactly what diagnostic cardiology needs. You aren’t trying to generate a creative new interpretation of an ECG. You’re trying to accurately classify a known arrhythmia or quantify cardiac function based on established medical facts. Look at a company like Tempus AI. Their entire approach to precision medicine, which started in oncology and is now moving into cardiology, is built on structured multimodal data. They use deep learning to connect the dots between genomic sequencing, clinical records, and pathology images to give doctors a clearer path for patient care. It’s about spotting real patterns in complex data to make better diagnostic and therapeutic choices, all resting on the reliability of structured models trained on real-world evidence (RWE).
The Data Moat and Model Interpretability Advantage
The real competitive edge for structured deep learning in cardiology comes from building a massive data moat. A company that has spent years collecting and carefully labeling a proprietary dataset of cardiac images, ECGs, and patient outcomes, all validated by expert cardiologists, has an asset that’s nearly impossible for a new competitor to replicate. The model’s performance is a direct result of that data’s quality and scale. On top of that, these structured models give you a better shot at interpretability. While nobody has a perfectly transparent AI, techniques like saliency maps can show a clinician exactly which part of an ECG waveform the algorithm found suspicious, letting the human expert make the final call. This isn’t a “black box” spitting out orders. It’s an intelligent tool that augments the clinician’s own expertise, which is a much easier sell to doctors and regulators.
Working through the Regulatory Field: Predictability Over Novelty
Getting a medical device to market means getting through the FDA, and their rules for SaMD are all about safety, effectiveness, and predictability. To get a 510(k) clearance or a De Novo classification, you have to run rigorous clinical studies proving your AI performs as well as or better than the current standard of care. For a generative AI, whose whole point is to create novel outputs, proving that it will perform consistently without any dangerous, unscripted hallucinations is a massive challenge. How do you manage that inside the FDA’s framework for a Predetermined Change Control Plan (PCCP), which demands a controlled plan for how your model will evolve? It’s a regulatory nightmare. Structured deep learning models, on the other hand, fit this process perfectly, especially when they’re developed under Good Machine Learning Practice (GMLP) principles and a certified Quality Management System (QMS) like ISO 13485. Their performance is deterministic and can be continuously monitored, giving the FDA the predictable, verifiable data it needs for clearance. FDA guidance on Good Machine Learning Practice.
Investment Thesis: Prioritizing Efficacy and Evidenced Outcomes
For Seed and Series A investors, this isn’t an academic debate, it’s a fundamental screen for finding a company that can actually survive and scale in health tech. Any company can call itself “AI-native,” but in a clinical context, that label only means something if the AI was built from the ground up on a foundation of evidence. The AI-native health companies that win are the ones whose core product is built around an AI that was:
- Trained on real patient outcomes data.
- Operating within defined clinical guardrails.
- With published evidence of efficacy.
Companies like Hello Heart prove this model works for managing chronic disease, using structured data to produce real, measurable improvements for patients. In diagnostic cardiology, the winners will be the ones that can show their tool improves accuracy, cuts down clinician busywork, and leads to better outcomes, all supported by clinical trials. If you go through the FDA database of cleared AI/ML medical devices, you see the story clearly: the vast majority of cleared cardiac software is built for classification, segmentation, and quantification from structured data, not for generating text or images for a primary diagnosis. This won’t change until generative AI somehow solves its reliability problem. So for investors, the path is clear: be deeply skeptical of generative AI pitches for core diagnostics and put your money on companies with defensible data moats, proven structured deep learning expertise, and a concrete plan for working through the FDA and getting reimbursement through CPT codes or NTAP.
Methodology and Source Note
This analysis is based on published research from places like Stanford Medicine, official regulatory guidance from the FDA, and public information about AI medical devices. When we talk about the types of AI models with FDA clearance, we’re drawing that from ongoing reviews of the FDA’s public databases and cross-referencing with the technical specs companies release. We stick to verifiable information and hard clinical evidence, not marketing claims.
Frequently Asked Questions
Why is generative AI considered unsuitable for cardiac diagnostics, despite its general advancements?
Generative AI, including LLMs, is prone to ‘hallucination,’ producing factually incorrect or nonsensical outputs that appear plausible. In cardiac diagnostics, where accuracy is paramount, this unreliability can lead to catastrophic false negatives or unnecessary invasive procedures, making it unacceptable for clinical use according to regulatory standards.
What type of AI is more appropriate for cardiac diagnostics, and why?
Structured deep learning models are more appropriate for cardiac diagnostics. They excel at identifying specific patterns within highly organized, labeled datasets, aligning with the need to accurately classify, quantify, and predict based on established medical knowledge rather than generating novel interpretations.
What is the significance of a ‘data moat’ for AI companies in cardiac diagnostics?
A robust ‘data moat’ refers to proprietary, meticulously labeled datasets of cardiac imaging, ECGs, and patient outcomes. This curated data forms the bedrock for highly accurate and generalizable structured deep learning models, providing a significant competitive advantage and making it difficult for new entrants to replicate.
How do regulatory bodies like the FDA view generative AI versus structured deep learning for medical devices?
The FDA prioritizes safety, effectiveness, and predictability for medical devices. Generative AI’s probabilistic nature and risk of unpredicted hallucinations present a formidable hurdle for proving consistent, error-free performance. Structured deep learning models, with their more controlled and verifiable outputs, align better with these stringent regulatory requirements.
